Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Refludan er større end risiciene ved behandling af heparin- induceret trombocytopeni og tromboembolisk sygdom.
As the disease is very severe, and there is no other effective treatment approved, the Committee for Medicinal Products for Human Use (CHMP) decided that Refludan’ s benefits are greater than its risks for the treatment of patients with heparin-induced thrombocytopenia and thromboembolic disease.